公开(公告)号：EP3845639A1

公开(公告)日：2021-07-07

申请号：EP19856074.0

申请日：2019-08-26

申请人： Mican Technologies Inc. ,  Kumamoto University ,  Osaka University

发明人： MIYAZAKI, Kazuo ,  YAMANAKA, Atsushi ,  OKADA, Minoru ,  SENJYU, Satoru

IPC分类号： C12N5/10 ,  C12N5/0784 ,  C12N5/0786 ,  C12N7/00 ,  C12N7/04 ,  C12N15/12 ,  C12Q1/04 ,  G01N33/15 ,  G01N33/50 ,  A61K39/12 ,  A61P31/12

摘要： The present invention has been made in view of a problem regarding stability, reproducibility, economy, and easiness of operation in studies for a monocyte- or dendritic cell-mediated infectious microorganism, and is directed to provide a method for maintenance culturing a monocyte- or dendritic cell-mediated infectious microorganism utilizing a monocyte having a proliferative capacity. The present invention is based on the finding that a dengue virus efficiently infects a proliferable human monocytic cell obtained by introducing a gene into a CD14-positive cell and a cell having a phagocytic capacity obtained by inducing the monocytic cell to differentiate (e.g., dendritic cell) and proliferates therein. Thus, provided is a novel method for evaluating a pharmaceutical such as a compound or a vaccine for treating an infection with a monocyte- or dendritic cell-mediated infectious microorganism.

公开(公告)号：EP4227407A1

公开(公告)日：2023-08-16

申请号：EP21877683.9

申请日：2021-10-06

申请人： Mican Technologies Inc. ,  OSAKA UNIVERSITY

发明人： SHIMIZU, Jun ,  TANGA, Naomi ,  YAMADA, Misuzu ,  MIYAZAKI, Kazuo ,  SHIODA, Tatsuo ,  NAKAYAMA, Emi ,  SASAKI, Tadahiro ,  KOKETSU, Ritsuko

IPC分类号： C12N5/10 ,  C07K16/10 ,  C12N5/0784 ,  C12N5/0786 ,  C12N7/02 ,  C12N15/19 ,  C12N15/57 ,  C12Q1/6851 ,  C12Q1/686 ,  C12Q1/70 ,  G01N33/15 ,  G01N33/50 ,  G01N33/53 ,  G01N33/68

摘要： The present invention provides human cells that can be stably infected with coronavirus, as human cells for research on infection with coronavirus such as SARS-CoV-2, as well as, by utilizing the cells, a method for confirming the presence of a coronavirus in a sample, a method for producing a coronavirus, and a method for evaluating the presence or absence of anti-coronavirus activity of a test sample or a substance having an anti-coronavirus neutralizing action in a test sample. Specifically, the present invention relates to a method for preparing a coronavirus-infectious immortalized human myeloid cell, including introducing ACE2 and TMPRSS2 into an immortalized human myeloid cell, and the like.

公开(公告)号：EP4349976A1

公开(公告)日：2024-04-10

申请号：EP22811031.8

申请日：2022-03-31

申请人： Mican Technologies Inc. ,  Japan as Represented by The Director-General of National Institute of Infectious Diseases ,  OSAKA UNIVERSITY

发明人： SUZUKI, Ryosuke ,  MATSUDA, Mami ,  MURAMATSU, Masamichi ,  SAITO, Kyoko ,  FUKASAWA, Masayoshi ,  HANADA, Kentaro ,  YAMANAKA, Atsushi ,  MIYAZAKI, Kazuo ,  YAMADA, Misuzu ,  SHIMIZU, Jun

IPC分类号： C12N7/01 ,  C12N5/10 ,  C12N15/33 ,  C12Q1/02 ,  G01N33/53

摘要： The present invention aims to provide a method for testing the function of antibodies that uses safe antigens and gives results more quickly. The present invention relates to a method for determining antibody-dependent enhancement ability of antibodies, including contacting, in the presence of a test antibody, Fcγ receptor-expressing cell with single round infectious virus particles containing a gene with a region encoding a labeled protein and a region encoding non-structural (NS) proteins 1 to 5 of the yellow fever virus genome, a capsid protein of a virus, and an outer shell protein (Envelope) of a virus, wherein when the measured label is greater than that of a negative control cell, the test antibody is determined to have an antibody-dependent enhancement ability, and the like.

公开(公告)号：EP4063493A1

公开(公告)日：2022-09-28

申请号：EP20891338.4

申请日：2020-11-19

申请人： Mican Technologies Inc. ,  Nissui Pharmaceutical Co., Ltd.

发明人： MIYAZAKI, Kazuo ,  SHIMIZU, Jun ,  TANAKA, Yoshitaka

IPC分类号： C12N5/0784 ,  C12N5/10 ,  C12Q1/02 ,  G01N33/15 ,  G01N33/50 ,  G01N33/53 ,  G01N33/68

摘要： [Problem]
To find a method having higher stability, reproducibility, economic efficiency, and operation easiness in an evaluation method of safety of a substance in vitro, by using human immortalized myeloid cells.
[Solving Means]
A method for evaluating the skin sensitizing property and/or the pyrogenic property of a test substance, a method for detecting a skin sensitizer and/or a pyrogen in a sample, and a method for evaluating the action of a sample on a function of immune cells, each using human immortalized myeloid cells and including measuring the production amount of IL-6 and/or IL-8 in a culture medium of human immortalized myeloid cells.